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Cyclosporin A (CsA) inhibits opening of the mitochon-
drial permeability transition pore (MPTP), a critical
event in some forms of necrotic and apoptotic cell death,
by binding to cyclophilin D (CyP-D) and inhibiting its
peptidyl-prolyl cis-trans isomerase (PPIase) activity.
Sanglifehrin A (SfA), like CsA, exerts its immunosup-
pressive action by binding to cyclophilin A but at a
different site from CsA, and unlike the latter, SfA does
not inhibit calcineurin activity. Here we demonstrate
that SfA inhibits the PPIase activity of CyP-D (K0.5 2 nM)
and acts as a potent inhibitor of MPTP opening under
both energized and de-energized conditions. However,
unlike CsA, the dose-response curve for inhibition by
SfA is sigmoidal rather than hyperbolic, suggesting a
multimeric structure for the MPTP with cooperativity
between subunits. Furthermore, SfA does not prevent
CyP-D binding to submitochondrial particles or deter-
gent-solubilized adenine nucleotide translocase (ANT),
implying that CyP-D binding to the ANT does not require
PPIase activity but pore opening does. Once bound to the
MPTP, SfA is not readily dissociated, and inhibition of
pore opening is maintained following extensive washing.
To investigate the potential of SfA as an inhibitor of cell
death in vivo, we used the Langendorff perfused rat heart.
SfA caused a time-dependent inhibition of the MPTP that
was maintained on mitochondrial isolation to a greater
extent than was CsA inhibition. We demonstrate that SfA,
like CsA, improves the recovery of left ventricular devel-
oped pressure during reperfusion after 30 min of global
ischemia and greatly reduces lactate dehydrogenase re-
lease, implying inhibition of necrotic damage. Because
SfA does not inhibit calcineurin activity, our data suggest
that it may be more desirable than CsA for protecting
tissues recovering from ischemic episodes and for study-
ing the role of the MPTP in cell death.
A critical event in some forms of necrotic and apoptotic cell
death is the opening of the mitochondrial permeability transi-
tion pore (MPTP)1 (1–4), the formation of which is widely
thought to involve an interaction between the adenine nucleo-
tide translocase (ANT) and cyclophilin D (CyP-D (1, 2). To date,
the most specific inhibitor of the MPTP is cyclosporin A (CsA)
(5), which acts by inhibiting the peptidyl-prolyl cis-trans
isomerase (PPIase) activity of CyP-D (6, 7). Indeed, CsA can act
as a potent inhibitor of both apoptotic and necrotic cell death
under some circumstances (1–3). Nevertheless, inhibition of
cell death by CsA does not provide definitive evidence for a
critical role of the MPTP in the process, because CsA exerts
other effects on cell function. In particular, the immunosup-
pressant action of the drug is mediated through inhibition of
calcineurin, a calcium-activated protein phosphatase involved
in the regulation of gene expression and other intracellular
functions (8–10). However, there are CsA analogues such as
N-Me-Ala-6-cyclosporin A and N-Me-Val-4-cyclosporin A that
do not inhibit calcineurin activity and yet still inhibit the
PPIase activity of CyP-D, antagonize the opening of the MPTP
and protect cells from apoptotic and necrotic cell death (11–13).
In this paper we investigate another immunosuppressant drug,
sanglifehrin A, that is unrelated to CsA but like CsA binds
tightly to cyclophilin A (CyP-A) with a K0.5 of 4–7 nM, inhibit-
ing its PPIase activity (K0.5 13 nM). However, unlike the CyP-
ACsA complex, the CyP-ASfA complex does not inhibit cal-
cineurin (14, 15). Rather, SfA specifically blocks T cell
proliferation in response to interleukin 2 through a mechanism
involving an NFB-mediated increase in the expression of the
tumor suppressor genes p53 and p21, with the latter binding to
and inhibiting the appearance of cell cycle kinase activity cyclin
E-Cdk2 (14, 16, 17).
If SfA were able to bind tightly to CyP-D and inhibit its
PPIase activity and the opening of the MPTP, its lack of effect
on calcineurin might make it an alternative to N-Me-Ala-6-
cyclosporin A and N-Me-Val-4-cyclosporin A in studying the
role of the MPTP in cell death. Here, we demonstrate that SfA
is as potent as CsA as an inhibitor of the PPIase activity of
CyP-D and of MPTP opening. It is also able to improve func-
tional recovery of rat hearts reperfused following an ischemic
episode, as well as reduce necrotic damage. However, SfA
shows some important differences from CsA in its mode of
action on the MPTP. It demonstrates a sigmoidal rather than a
hyperbolic dose-response curve for MPTP inhibition and does
not prevent CyP-D binding to the ANT. These data provide new
insights into the molecular mechanism of the MPTP.
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Preparation of Mitochondria and Submitochondrial Particles
(SMPs)—Percoll-purified rat liver mitochondria and SMPs were pre-
pared as described previously (18, 19). For measurement of MPTP
opening under de-energized conditions, they were stored on ice over-
night before use to deplete them of adenine nucleotides (18).
MPTP Opening—The opening of the MPTP was determined under
energized or de-energized conditions by following the decrease in light
scattering (monitored as A520) that accompanies mitochondrial swelling
at 25 °C (6). The buffer for energized conditions was 125 mM KCl, 20 mM
Mops, 10 mM Tris, 2 mM potassium Pi, 2 mM succinate, 0.5 M rotenone,
pH 7.2, and for de-energized conditions was 150 mM KSCN, 20 mM
Mops, 10 mM Tris, 2 mM nitrilotriacetic acid, 2 M A23187, 0.5 M
rotenone, 0.5 M antimycin A, pH 7.2. Additions of CsA (Calbiochem) or
SfA (Novartis) were made as required. MPTP opening was initiated by
addition of CaCl2 to give the free [Ca
2] indicated. The sensitivity of the
MPTP to [Ca2] was also determined by following the shrinkage of
pre-swollen mitochondria (as an increase in A520) upon the addition of
polyethylene glycol (PEG-2000) as described previously (18, 20). De-
energized buffer was used, and pre-swollen mitochondria were prein-
cubated for 2 min with the required [Ca2] and other additions before
initiation of shrinkage by the addition of 7% (w/v) PEG. The rates of
swelling and shrinking of mitochondria were determined by differenti-
ation of the A520 time course (18).
PPIase Activity of CyP-D—The PPIase activity of recombinant CyP-D
(produced by thrombin cleavage of GST-CyP-D (21)) was determined by
following the rate of hydrolysis of N-succinyl-Ala-Ala-Pro-Phe-p-nitro-
anilide by chymotrypsin as described previously (6, 7). Chymotrypsin
only hydrolyzes the trans form of the peptide, and hydrolysis of the cis
form, the concentration of which is maximized by using a stock dis-
solved in trifluoroethanol containing 470 mM LiCl (22), is limited by the
rate of cis-trans isomerization.
CyP-D Binding to SMPs—Recombinant CyP-D (10 g), prepared as
described previously (21), was added to 100 g of SMPs (4 mg pro-
tein/ml in isolation medium) and incubated for 15 min at 22 °C before
sedimenting by centrifugation (157,000  g for 5 min at 4 °C). After
being washed once in isolation buffer, bound CyP-D was determined by
SDS-PAGE and Western blotting with anti-CyP-D antibodies (21).
Binding of ANT to GST-CyP-D—This was performed essentially as
described previously using detergent-solubilized purified inner mito-
chondrial membrane and recombinant GST-CyP-D bound to glutathi-
one-Sepharose (21). When required, the bound GST-CyP-D was prein-
cubated with CsA or SfA (25 M) for 15 min at 22 °C prior to the
addition of solubilized inner mitochondrial membranes. After extensive
washing the specifically bound protein was then eluted with glutathi-
one and analyzed by SDS-PAGE and Western blotting with anti-ANT
antibodies (21).
Heart Perfusion—Isolated rat hearts were perfused in the Langen-
dorff mode as described previously (23) with continuous monitoring of
left ventricular developed pressure (LVDP) and left ventricular end
diastolic pressure (LVEDP) using a pressure transducer connected to a
water-filled balloon inserted into the left ventricle. Following control
perfusion for 50 min, with the addition of CsA or SfA as required,
perfusion was halted to initiate global isothermic (37 °C) ischemia.
After 30 min, ischemia perfusion was restarted and was continued for
10 min in the presence of drug and a further 20 min in its absence.
Samples of perfusate were collected prior to ischemia and every 1 min
during reperfusion for the determination of lactate dehydrogenase ac-
tivity spectrophotometrically.
RESULTS
SfA Inhibits the PPIase Activity of CyP-D and MPTP Open-
ing—In Fig. 1 we show that SfA inhibits the PPIase activity of
recombinant CyP-D with a Ki (S.E.) of 2.2 0.7 nM, a potency
similar to that of CsA (6, 7). In Fig. 2a we demonstrate that
submicromolar concentrations of SfA inhibit opening of the
MPTP of energized mitochondria induced by 100 nmol of
Ca2/mg of mitochondrial protein. However, the concentration
dependence of inhibition was complex, with the lowest concen-
tration of SfA (100 nM) failing to exhibit any inhibition no
matter how long the mitochondria were exposed to the drug.
We have previously shown (18) that energized mitochondria
are not ideal for probing the mechanism of the MPTP because
many factors can affect the sensitivity of pore opening to
[Ca2]. These include changes in membrane potential, matrix
adenine nucleotide concentrations, and calcium transport (18).
In addition, the accumulation of calcium in the presence of
phosphate can lead to an increase in light scattering prior to
pore opening that becomes dominant when the MPTP is inhib-
ited (6, 24–28). This is apparent in Fig 2a. For this reason, we
routinely use de-energized conditions (iso-osmotic KSCN buffer
with respiratory chain inhibitors) in the presence of the cal-
cium ionophore A23187 to ensure that calcium equilibrates
across the inner mitochondrial membrane. Mitochondria are
also stored overnight following their preparation because they
lose a fair proportion of their adenine nucleotides during the
first few hours of storage on ice, which causes the sensitivity of
the MPTP toward calcium to change over this period. Using
these conditions it is possible to obtain detailed dose-response
curves for CsA analogues allowing calculation of K0.5 values
that closely match the Ki for inhibition of the PPIase activity of
CyP-D (6, 7).
The data of Fig. 2b show some typical traces for the inhibi-
tion of the MPTP by CsA and SfA under such de-energized
conditions, whereas in Fig. 3 we present detailed dose-response
curves. These data show clearly that CsA and SfA behave
differently. Whereas inhibition by CsA is progressive and can
be fitted to the equation for binding to a single site as described
previously (6, 7), the inhibition by SfA is sigmoidal with little or
no inhibition apparent at low inhibitor concentrations. How-
ever, a steep concentration dependence for inhibition developed
as SfA reached a concentration at which CsA gave about 50%
inhibition, the value being dependent on the concentration of
mitochondria in the assay (Fig. 3b). The concentration of SfA
required to inhibit pore opening by 80% was almost identical
to that when CsA was used (Fig 3a), consistent with both
inhibitors associating with the same target protein (CyP-D).
SfA also inhibited the MPTP when assayed using the shrinkage
assay, and here too the concentration dependence for inhibition
was sigmoidal as shown in Fig. 4a. The effect of SfA, like that
by CsA (18), was to decrease the sensitivity of the MPTP to
[Ca2] as shown in Fig. 4b. Thus, even in the presence of a
concentration of SfA that gave maximal inhibition (1 M), the
pore could be opened at higher [Ca2].
Distinct Effects of SfA and CsA on CyP-D Binding to SMPs
and Solubilized ANT—The effects of SfA and CsA on CyP-D
binding to SMPs were compared, and the data are shown in
Fig. 5a. SfA slightly increased the binding of recombinant
CyP-D to SMPs (lane 4), unlike CsA, which greatly reduced
binding (lane 3) as observed previously (12, 20). In nine such
experiments the mean binding of CyP-D in the presence of SfA
as percentage of control (S.E.) was 132  12% (p  0.05),
whereas for CsA the binding was reduced to 34  8% (p 
0.001). Treatment of the CyP-D with SfA before (lane 7) or after
(lane 6) CsA treatment overcame the CsA inhibition of CyP-D
binding. A slight reversal of CyP-D binding to SMPs was de-
tected when CsA was added after CyP-D was already bound
(lane 8), but again no effect of SfA was observed (lane 9). These
data suggest that CsA binds to CyP-D at the same site as the
ANT, whereas SfA binds to a distinct site that actually en-
hances CyP-D binding to the ANT while displacing bound CsA.
Further evidence in favor of this interpretation was obtained
when the effects of CsA and SfA on the binding of ANT present
in detergent-solubilized inner mitochondrial membranes to a
GST-CyP-D affinity column were studied (Fig. 5b). ANT bind-
ing was enhanced by pretreatment of mitochondria with dia-
mide and inhibited by pretreatment of the GST-CyP-D with
CsA as found previously (21). In contrast, SfA did not prevent
binding, and in the case of diamide-treated mitochondria, the
binding of ANT was actually increased by SfA.
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SfA Protects the Ischemic Heart from Reperfusion Injury—
The MPTP has now been recognized as playing a critical role in
both necrotic and apoptotic cell death, and evidence for this has
come from the ability of CsA to protect cells from a variety of
death signals (1–3). We and others (23, 29, 30) have demon-
strated that the necrotic damage associated with reperfusion of
the ischemic rat heart (irreversible reperfusion injury) can be
protected by pretreatment of the heart with CsA, with optimal
effects being observed at 0.2 M. Thus it would be expected that
SfA might act in the same manner. Initial experiments using
Langendorff perfused rat hearts subjected to 30 min of global
ischemia followed by reperfusion failed to show any protective
effects of 0.2 M SfA when functional recovery was determined
by measurement of LVDP and LVEDP. One explanation of why
SfA gave no protection under these conditions would be that it
fails to reach the mitochondria in the perfused heart. To test
this possibility the experiments reported in Fig. 6 were
performed.
In Fig. 6a we investigated whether, following treatment of
mitochondria with SfA, the drug remains bound to CyP-D
through extensive washing of mitochondria in the absence of
SfA. Mitochondria pretreated with 1 M CsA and then washed
free of CsA exhibited greatly reduced MPTP opening in re-
sponse to Ca2 when compared with untreated mitochondria,
although the inhibition was not as complete as when the CsA
was added directly to the assay. These data suggest that some
CsA dissociated from CyP-D during the washing. In contrast,
mitochondria pretreated with 1 M SfA maintained complete
inhibition of the MPTP following washing. These data indicate
that SfA dissociates from CyP-D less readily than CsA. In
addition, they imply that if SfA has access to mitochondria
within the perfused heart, this will be detected as an inhibition
of the MPTP in subsequently isolated mitochondria. In Fig. 6b
we demonstrate that this is the case.
In hearts pretreated with 0.2 M CsA for 3 min, the condi-
FIG. 1. Inhibition of PPIase activity of CyP-D by SfA. Recombi-
nant CyP-D (6 pmol) was preincubated at 10 °C for 5 min in 3.5 ml of
PPIase assay buffer (see “Experimental Procedures”) with the concen-
trations of SfA shown. The assay was started by the addition of peptide,
and initial rates of reaction were determined by first order regression
analysis of the time course of change in A520. The Ki (S.E.) derived by
fitting the data to the equation for a tight binding inhibitor (6) was
2.2  0.7 nM.
FIG. 2. Inhibition of the MPTP by SfA. In panel a, MPTP opening
in rat liver mitochondria (1.5 mg protein/ml) was assayed under ener-
gized conditions (see “Experimental Procedures”) by monitoring the
decrease in A520 with a split beam spectrophotometer after the addition
of 100 M CaCl2 to the sample cuvette. When present, SfA or CsA were
added at the concentrations shown at 2 min before calcium addition. In
panel b the protocol was similar, but de-energized conditions were
employed and pore opening initiated by the addition of CaCl2 to give a
calculated free concentration of 100 M.
FIG. 3. Concentration dependence of the inhibition of the
MPTP by SfA. In both panels the extent of MPTP opening was deter-
mined from the rate of swelling in experiments similar to those shown
in Fig 2b but with CsA or SfA added 2 min before CaCl2 at the
concentrations indicated. In panel a the protein concentration was 1.5
mg/ml, whereas in panel b the concentration of mitochondria was varied
as indicated.
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tions found optimal for protecting hearts from reperfusion in-
jury (23), some inhibition of MPTP opening was detected at
both 100 and 200 M Ca2. In contrast, treatment with 0.2 M
SfA for 5 min gave no detectable inhibition of the MPTP,
consistent with its inability to protect hearts from reperfusion
injury under these conditions. However, when hearts were
perfused with 1 M SfA for 10 min, almost total inhibition of the
MPTP could be demonstrated. This inhibition is unlikely to be
due to the carry over of SfA into the isolation buffer because the
total amount of extracellular medium in the heart (about 0.5
ml) contains only 500 pmol of SfA. This compares with a mito-
chondrial CyP-D content of the heart of2000 pmol (calculated
from data in Refs. 11 and 31). However, we have confirmed this
conclusion experimentally in two ways. First, when 1 M SfA
was perfused through the heart for only 1 min prior to mito-
chondrial preparation, opening of the MPTP was similar to
control mitochondria (data not shown). Second, when hearts
were exposed to 1 M SfA for 10 min and then the SfA removed
by a 30-s perfusion with SfA-free buffer, the MPTP opening in
subsequently isolated mitochondria remained inhibited even at
1 mM calcium (Fig. 6b). Thus it would be predicted that these
conditions should protect hearts from reperfusion injury; the
data of Fig. 7 demonstrate that this is indeed the case.
In Fig. 7a we show that pretreatment of hearts with 0.2 M
CsA for 3 min before 30 min of global ischemia greatly im-
proved function recovery of the heart during reperfusion, as
reflected in the greater LVDP (69  8% of pre-ischemic values,
cf. control value of 26  8%; p  0.01) and lower LVEDP (37 
6 mm Hg, cf. control value of 64  6; p  0.01). These data
confirm previous data from our and other laboratories (23, 30).
Very similar results were obtained when hearts were pre-
treated with 1 M SfA for 10 min, with recovery of LVDP being
79  10% of pre-ischemic values and the LVEDP being 33  4
mm Hg (both p  0.01 versus controls). To confirm that this
functional protection reflects an inhibition of necrotic cell death
during reperfusion, lactate dehydrogenase release was deter-
mined, and the results are reported in Fig. 7b. It is clear that
both SfA and CsA greatly reduce lactate dehydrogenase release
coincident with their protection of heart function.
DISCUSSION
The Molecular Mechanism of the MPTP—We have shown
previously (6, 7, 18, 20, 21, 32) and confirm here that CsA binds
to CyP-D, inhibiting its PPIase activity and preventing its
binding to the ANT. This would appear to be the mechanism by
which CsA inhibits opening of the MPTP as we originally
proposed (6). In contrast, SfA inhibits the PPIase activity of
CyP-D (Fig. 1) and inhibits MPTP opening (Figs. 2–4) without
preventing CyP-D binding to the ANT (Fig. 5). It seems prob-
able that both CsA and SfA act to inhibit the MPTP via their
binding to CyP-D because the concentration of each required to
inhibit pore opening by 80% is almost identical (Fig. 3a).
However, our data imply that SfA and CsA bind to CyP-D at
different sites. In both cases the PPIase activity is inhibited,
but only for CsA does binding of the inhibitor prevent binding
of CyP-D to the ANT. Thus the SfACyP-D complex can still
bind to the ANT but is unable to facilitate the conformational
change, triggered by [Ca2], that induces pore opening. This
allows a further conclusion to be drawn. Binding of CyP-D
alone is not sufficient to promote pore opening; a subsequent
conformational change, catalyzed by the PPIase activity of
FIG. 4. The effect of SfA on the calcium dependence of the
MPTP. In both panels the extent of MPTP opening was determined by
measuring the rate of shrinkage of pre-swollen mitochondria upon the
addition of 7% (w/v) PEG as described under “Experimental Proce-
dures.” In panel a the pre-swollen mitochondria were incubated for 2
min with 50 M [Ca2] and the concentration of SfA shown before the
addition of PEG to initiate shrinkage. In panel b the concentration of
Ca2 was varied as indicated in the absence or presence of 1 M SfA.
FIG. 5. CsA but not SfA prevents CyP-D binding to SMPs and
ANT binding to GST-Cyp-D. In panel a, recombinant CyP-D (10 g)
was preincubated for 15 min at 22 °C with 50 M CsA, 50 M SfA, or
solvent (ethanol) as indicated before the addition of SMPs. After incu-
bation for a further 15 min at 22 °C, bound CyP-D was determined by
SDS-PAGE and Western blotting as described under “Experimental
Procedures.” In lane 5, SfA and CsA were added together. In lane 6,
CyP-D was incubated with CsA for 15 min followed by SfA for 15 min,
whereas in lane 7, the order of addition of the inhibitors was reversed.
In lanes 8 and 9, the CsA and SfA were added after incubation of SMPs
with CyP-D, and incubation was continued for a further 15 min. In
panel b, inner mitochondrial membranes were prepared from rat liver
mitochondria after incubation in the presence or absence of 1 mM
diamide for 10 min at 22 °C. After detergent solubilization, they were
passed down a GST-CyP-D affinity column that had been preincubated
with or without 25 M CsA or SfA as described under “Experimental
Procedures.” Following extensive washing, bound proteins were eluted
with glutathione and analyzed by SDS-PAGE and Western blotting
with anti-ANT antibodies.
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CyP-D, must then occur that is inhibited by SfA. CsA prevents
the PPIase-dependent conformational change because it pre-
vents CyP-D binding, whereas SfA still allows CyP-D binding
but not the subsequent conformational change.
A further insight into the mechanism of the MPTP is pro-
vided by the sigmoidal nature of the concentration dependence
of pore opening by SfA (Figs. 3 and 4). These data imply that
SfA only inhibits pore opening once a significant proportion
(about 50%) of the matrix CyP-D has bound SfA. This contrasts
with CsA, where inhibition occurs directly in proportion to the
amount bound to CyP-D (Fig. 3) (6, 7, 20). The most probable
explanation of this observation is that the MPTP is a multi-
subunit complex, with the CyP-D-mediated conformational
change required to open the pore involving co-operative inter-
actions between the subunits. The simplest model, illustrated
in Fig. 8, would be that the ANT, which exists as a dimer, must
bind two CyP-D molecules to induce the conformational change
required to prime the MPTP to open upon triggering with Ca2.
Even if one of the two CyP-D molecules has SfA bound, the
conformational change will occur, but if both of the bound
CyP-D molecules are associated with SfA, the conformational
change cannot occur. However, a CyP-D-independent confor-
mational change of the ANT can also induce pore opening at
high levels of [Ca2] (33), which may explain why pore opening
can still be observed in the presence of the maximally inhibit-
ing concentration of SfA when higher levels of [Ca2] are em-
ployed (Fig. 4b).
It should be noted that our data do not eliminate other
models for the MPTP pore. Thus a membrane protein other
FIG. 6. SfA and CsA inhibit the MPTP in the perfused heart. In
panel a isolated rat heart mitochondria (2 mg/ml in isolation buffer)
were incubated in the presence or absence of 1 M CsA or SfA for 10 min
at 0 °C before sedimentation and two washes at 0.4 mg/ml. MPTP
opening under de-energized conditions (1 mg protein/ml) was monitored
(A520) following addition of Ca
2 at the concentration shown. The top
two traces represent control mitochondria to which 1 M CsA and SfA
have been added directly to the swelling assay, whereas the middle
traces show mitochondria pretreated with the drugs and then washed.
In panel b mitochondria were isolated from hearts perfused (Langen-
dorff mode) for 30 min in the absence of drug and then with the
concentration of CsA or SfA indicated for the times shown. Where
indicated, extracellular SfA was washed from the heart prior to mito-
chondrial preparation by perfusing it for 30 s with SfA-free buffer (5
ml). Assay of MPTP under de-energized conditions was performed as
described for panel a at a final protein concentration of 0.5 mg/ml. The
inset traces were performed with the same mitochondria as the traces
marked with an asterisk but with swelling initiated by addition of
[Ca2] at 100 as opposed to 200 M.
FIG. 7. SfA and CsA protect the ischemic rat heart from reper-
fusion injury. Rat hearts were perfused in the Langendorff mode, and
the left ventricular pressure was monitored continuously as described
under “Experimental Procedures.” After 50 min, perfusion hearts were
subject to 30 min of global isothermic ischemia followed by reperfusion.
Where required, 0.2 M CsA or 1 M SfA was added 3 or 10 min,
respectively, prior to ischemia. In panel a, greater functional recovery of
the SfA- and CsA-treated hearts after a 30-min reperfusion is reflected
in higher values for the LVDP and lower values for the LVEDP. Preis-
chemic values for the LVDP and LVEDP were 76  3.5 and 2.4  0.3
mm Hg, respectively (n  9) and were unaltered by either CsA or SfA.
Values of the LVDP after reperfusion are presented as a percentage of
the pre-ischemic value and were significantly greater (p  0.001) with
either SfA or CsA treatment, whereas values for the LVEDP were
significantly lower (p  0.001). In panel b, the release of lactate dehy-
drogenase (LDH) into the perfusate from the same hearts used in panel
a was measured as an indicator of necrotic cell death (*, p  0.05 for
CsA- or SfA-treated hearts versus controls).
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than the ANT may be the true target, or an additional target,
of CyP-D binding that is responsible for MPTP formation. In-
deed He and Lemasters (28) have suggested that many mis-
folded proteins may be capable of producing pores but are
prevented from doing so by the binding of CyP-D and other
chaperone proteins. This interaction may be disrupted by a
calcium-mediated conformational change induced by the PPI-
ase activity of CyP-D and blocked by CsA (28). Our data could
be reconciled with such a model by substituting a denatured
protein aggregate for the dimeric ANT shown in our scheme
(Fig. 8). However, the well documented effects on the MPTP of
adenine nucleotides and other ligands of the ANT, such as
bongkrekic acid and carboxyatractyloside (18), are strongly
suggestive that the ANT is the key membrane component
that operates under most pathophysiological conditions. So
too is the ability of the purified reconstituted ANT to form a
nonspecific channel at high [Ca2] (33), which in the presence
of CyP-D is opened at lower [Ca2] in a CsA-sensitive manner
(2, 34).
SfA May Be Better Than CsA as an Inhibitor of MPTP-
dependent Cell Death—To establish a role for the MPTP in
apoptotic cell death, many workers have relied on the use of
either CsA or bongkrekic acid as specific inhibitors of the
MPTP. In reality, neither of these agents is specific. The use of
bongkrekic acid is especially suspect, because its primary effect
is to inhibit ATP/ADP transport across the mitochondrial inner
membrane, a process that is fundamental to the metabolic and
bioenergetic integrity of almost all cells. The use of CsA is open
to criticism because when bound to CyP-A it inhibits the calcium-
dependent protein phosphatase, calcineurin, which has many
intracellular roles (8). This may, in part, explain why protec-
tion of hearts from reperfusion injury by CsA is critically de-
pendent on its concentration, with optimal effects being ob-
served at 0.2 M (23, 29, 30). There are CsA analogues such as
N-Me-Ala-6-cyclosporin A and N-Me-Val-4-cyclosporin A that
do not inhibit calcineurin activity and yet still inhibit the
PPIase activity of CyP-D, antagonize the opening of the MPTP
and protecting cells from apoptotic and necrotic cell death
(11–13). SfA also lacks the ability to inhibit calcineurin (14, 15)
but has the additional advantage of binding more tightly to
mitochondria than does CsA (Fig. 6). It thus represents an
important new specific tool for exploring the role of the MPTP
in cell death, which may have advantages over CsA analogues
as a protective agent against reperfusion injury and other
cellular stresses that cause cell death through MPTP opening.
The immunosuppressant activity of SfA is exerted by blocking
T cell proliferation in response to interleukin 2, through a
mechanism involving an NFB-mediated increase in the ex-
pression of the tumor suppressor genes p53 and p21, with the
latter binding to and inhibiting the appearance of cell cycle
kinase activity cyclin E-Cdk2 (14, 16, 17). Whether this action
of SfA on the cell cycle will have any detrimental effects when
the drug is used to inhibit reperfusion injury is unknown,
although the relatively short time scales involved in reperfu-
sion after ischemia would suggest not.
In conclusion, SfA provides new clues to the molecular mech-
anism of the MPTP and represents an important additional
tool for studying the role of the MPTP in both necrotic and
apoptotic cell death. The lack of any effect of SfA on calcineurin
activity may also make it an appropriate therapeutic agent for
the protection of tissues from reperfusion injury. Two situa-
tions of particular importance in this regard are the treatment
of stroke and coronary thrombosis, where reperfusion of the
ischemic area following clot disruption may induce necrotic or
apoptotic cell death. Finally, our data demonstrate that there
are two distinct sites on CyP-D that may be targeted in the
design of novel inhibitors of the MPTP that could be used
therapeutically to protect from reperfusion injury.
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